Towards a Clear Status for Probiotics in Europe

July 22, 2015. IPA Europe announces a launch event, “Towards a Clear Status for Probiotics in Europe”. September 30, 3016. Brussels. Register for event.

ISAPP Provides Input on Microbiome Research to the White House.

June 14, 2015. ISAPP responded to a request by the White House Office of Science and Technology Policy for input on microbiome research priorities. ISAPP response.

ISAPP Comments on CBER Proposal on INDs

May 28, 2015. ISAPP filed comments on an FDA-CBER proposal regarding CMC information required for INDs on probiotic research (Federal Register Notice).  ISAPP welcomes this proposal by CBER that the label on a commercially available product would be adequate to satisfy CMC information.  ISAPP comments.

ISAPP Responds to NIH-NCCIH Request for Research Direction.

May 12, 2015. ISAPP responds to the request by NIH-National Center for Complementary and Integrative Health for input into the Center’s future research efforts and priority setting. ISAPP response.

ISAPP Sponsored Prof. Bruno Pot to Speak at PAi | ISAPP

ISAPP sponsored Prof. Bruno Pot, Institut Pasteur Lille, to speak at the 2nd Annual Conference of the Probiotic Association of India. The conference titled “Probiotics and Microbiome: Gut and Beyond” was held November 3-4, 2014 in Delhi, India. For further details see the report.

The 8th annual Young Investigatory Grant for Probiotic Research has been announced

The 8th annual Young Investigatory Grant for Probiotic Research has been announced by Global Probiotics Council of Danone Nutricia Research and Yaklult Honsha Co., Ltd. Three annual grants of $50,000 USD supports innovative research on probiotics and gastrointestinal microbiota in the United States. Information.

October 7, 2014

Published today in Am J Reprod Immunol, and open access: Microbes Central to Human Reproduction. . The authors, let by Dr. Gregor Reid, summarize an ISAPP discussion group from 2014 meeting.

September 28, 2014

Health Point Productions has just released, “MicroWarriors” Special Edition. This Documentary Film on probiotics is a re-release with new footage from interviews featuring ISAPP board members, Prof. Gregor Reid and Mary Ellen Sanders. Some of the other experts include: Glenn Gibson PhD, Todd Klaenhammer PhD, Jose Saavedra MD, Robert Martindale MD, Simin Meydani PhD and Tri Duong PhD. Health Point Productions has offered to send a free copy of this Special Edition to the first 500 ISAPP Members who respond. Contact David Knight of Health Point Productions at microwarriorsmovie@nullsbcglobal.net.

September 26, 2014

ISAPP Board member, Michael Cabana, MD, MPH, joined 2 other experts (David Mills, Ph.D. and Mark Underwood, MD) in a continuing education program on Prebiotics, Probiotics, and the Microbiota. Official Audio CME Program of the American Academy of Pediatrics.

September 8, 2014

ISAPP filed comments regarding with the European Food Safety Authority regarding its intent to revise the guidance on scientific requirements for health claims on foods related to gut and immune function. ISAPP’s opinion is that EFSA should completely revise the guidance document, rather than limit comments to issues that have arisen in submitted dossiers. ISAPP also suggested that maintenance of homeostasis in all aspects of healthy human physiology should be considered as a beneficial health effect. EFSA document. ISAPP comments.

September 8, 2014

The Dannon Company Graduate Scholarship. The third Yogurt and Probiotics Fellowship Program offers a scholarship of $25,000 to a current or incoming graduate student who shows a strong interest in the research of nutritional and functional benefits of yogurt and probiotics. Candidates must be currently enrolled in or applying to a full-time graduate program. Applications due November 15, 2014. Information.

August 1, 2014

ISAPP files comments with the FDA regarding impact of Proposed Rule on labeling prebiotics on foods. ISAPP requests that the FDA modify the Proposed Rule as follows: (1) benefits of added fibers be explicitly expanded to include a broader range of potential physiological beneficial effects, (2) implement a phase-in period to allow adequate time to develop required substantiation, and (3) use a notification process rather than a pre-market approval process for substantiation. ISAPP Comment. FDA website link.

June 10, 2014

ISAPP’s consensus statement on the scope and appropriate use of the term probiotic was published today in Nature Reviews in Gastroenterology and Hepatology. The paper is open access. Key conclusions of the paper include that with minor edits, the 13-year old FAO/WHO definition of probiotic was endorsed; that sufficient evidence from human studies on commonly studied probiotic species allows use of the term ‘probiotic’ at a species-, not strain-, level; and undefined consortia of microbes such as those used for fecal microbial transplants do not fall under the scope of probiotics. The panel of experts comprised 12 internationally recognized scientists and the paper was endorsed by the ISAPP board of directors.

June 5, 2014

Meeting with CBER. On May 22, ISAPP’s Executive Science Officer (Mary Ellen Sanders) and Daniel Merenstein MD (Georgetown University) met with Peter Marks MD PhD, Deputy Director of Center for Biologics Evaluation and Research/FDA, and three other CBER representatives, to discuss CBER oversight of probiotic research as investigational new drugs. Concerns were expressed regarding requiring phase 1 safety studies, the lack of a waiver option, and inhibition of investigator-initiated studies. The meeting was a productive beginning to these discussions. Report.

May 1, 2014

The Yogurt in Nutrition Initiative announced a request for research proposals focused on health benefits associated with yogurt consumption. The competition is for one $30,000 USD grant. Research teams from public organizations or researchers at universities or hospitals may apply. The deadline for submission of applications is June 30, 2014. This call is supported by Danone Institute International in collaboration with the American Society for Nutrition (ASN) and the International Osteoporosis Foundation (IOF).

April 28, 2014

ISAPP board members, Gregor Reid and Mary Ellen Sanders, were interviewed by Shane Starling of Nutraingredients for a new documentary film, “MicroWarriors” The Special Edition. The special edition will be a completely re-editied and mastered version from the 2011 probiotic documentary film, “MicroWarriors” The Power of Probiotics. In addition, it will include new graphics and images, plus bonus material added and narration by Leonary Nimoy. The special edition film will be released in the Spring of 2014. MicroWarriors 2: The Origin and the Destiny is currently in production and will be released in the Fall/Winter of 2014. Information. Nutraingredients article with video interview.

April 8, 2014

ISAPP filed comments with the FDA on its guidance, which requires that essentially all human research to evaluate functional effects of foods be conducted under an IND. ISAPP requested that FDA revise the current guidance to remove their requirement for INDs for human research conducted on foods and that the guidance make it clear that prebiotics and probiotics have lawful, recognized food uses, which should be able to be researched in the USA without an IND.

Comments by the law firm, Hyman, Phelps & McNamara, also are of interest.

March 31, 2014

Webcasts of the lectures and workshop wrap-ups from the Gut Microbiota for Health World Summit (convened in Miami, March 8-9, 2014) are now available. Click here.

March 11, 2014

ISAPP joined the American Society of Nutrition, Institute of Food Technologists, ILSI-North America and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition in a meeting March 5 with FDA’s Center for Food Safety and Applied Nutrition to share concerns with a guidance that stipulates human research conducted on functional endpoints for foods requires an investigational new drug (IND) application. Dr. James Heimbach represented ISAPP and, along with ASN’s Sarah Ohlhorst, filed this report. Referenced Survey Results. See related posts February 25, February 5, 2014, November 26, 2013 and September 25, 2013.

February 25, 2014

ISAPP will meet March 5 with FDA’s Center for Food Safety and Applied Nutrition to discuss conducting human research on foods. The FDA made it clear in a guidance from September 2013 that human research conducted on functional endpoints for foods requires an investigational new drug (IND) application. However, the FDA re-opened the comment period on that guidance, and ISAPP – along with American Society of Nutrition, Institute of Food Technologists and ILSI-North America – will share concerns with CFSAN that the IND requirement for food research is misguided. As succinctly stated by Dr. James Heimbach, who will be representing ISAPP at the meeting, “A substance can’t be an investigational new drug unless it is a drug, and FDA is attempting to declare legitimate food ingredients that provide benefits other than taste or aroma to be drugs.” See related posts from February 5, 2014, November 26, 2013 and September 25, 2013.

February 24, 2014

On February 11, ISAPP, represented by Mary Ellen Sanders (executive director), Daniel Merenstein, Greg Leyer (Sr. ISAPP-IAC representative) and Chris Cifelli (Jr. ISAPP-IAC representative), met with Mr. Richard Cleland, Assistant Director, Division of Advertising Practices with the Federal Trade Commission to gain a better understanding of FTCs perspective on conducting research intended to substantiate structure/function or health claims for foods in the United States. Mr. Cleland’s forthright approach in his responses was much appreciated. This report itemizes the questions posed by ISAPP and summarizes the responses provided by Mr. Cleland.

February 5, 2014

The FDA is re-opening comments on portions of its Guidance on Determining if Human Research Studies Require an Investigational New Drug Application. ISAPP intends to file comments reflecting concerns that the current guidance (published in final form September 2013) unduly restricts human research on functional properties of foods and supplements, harming U.S. researchers, consumers and industry. Comments due to the FDA April 7, 2014. Submit comment. See related Latest News posts on September 25, 2013 and November 26, 2013.

January 10, 2014

World Gastroenterology Organisation released a new webcast “Irritable Bowel Syndrome (IBS): What is it, what causes it and can I do anything about it?”; an educational program for the general public. The webcast was developed from the WGO World Digestive Health Day 2012 Campaign and covers the following topics: What is IBS?, How to communicate symptoms to help the doctor make the right diagnoses, Progress in IBS, Could it be something else?, What can I do to deal with my symptoms?, How about diet or dietary supplements?, Managing IBS, and Living with IBS.

January 9, 2014

U.S. Pharmacopeia (USP) is accepting comments on a proposed monograph for testing the identity, concentration and purity of Bacillus coagulans GBI-30, 6086. As the first probiotic monograph with USP, this is a noteworthy development. USP press release. USP Food Ingredients.

January 7, 2014

Law firm expresses concern that the FDA seeks to greatly constrict medical food category in the United States. See blog post by Hyman, Phelps & McNamara, P.C., Medical Food Draft Guidance – Has the FDA Bitten off More than it Can Chew?